HEURIS INC. — Department of Health and Human Services STTR Phase I: 102

Description

Quality assurance QA is a critical component of radiation oncology that ensures both effective treatment delivery and patient safety Over the last decade dQA is now particularly important asramatic innovations in treatment delivery technologiesy have led to increasingly sophisticated and complex treatments that are difficult to adequately verify with conventional dosimetric verification systems Corresponding innovations in verification technologies haves lagged behind generating a potentially dangerous imbalance where traditional verification systems lack sufficient capability to adequately verify these new treatmentsopportunity for new paradigm changing comprehensive D dosimetry QA systems In this proposal we address this lack and need by developing a novel truly D treatment verification measurement system based on a D radiochromic dosimeter Presage with optical CT readout There are two specific aims i to optimize two advanced prototype Presage formulations see below and ii to optimize a novel low cost D optical scanner The objective of the first aim is to optimize two advanced prototype Presage formulations for application to remote and re useable D dosimetry respectively AIn remote dosimetry highly stable prototype Presage formulation will be optimized that will enable remote dosimetry consisting of dosimeters are shipmentped from a central base institution to a remote institution for irradiation and then shipped back to the base institution for readout and analysis A post irradiation stableThis formulation formulation will improve enable the comprehensiveness of remote credentialing and or auditing tests The second sub aim is to optimize aA second re useable formulation formulation will be optimized where the post irradiation optical densitydosimeter gradually `clearsandapos within weeks and the dosimeter can then be re used This formulation will allow economic in house use for centers with a readout optical CT system Potential formulation modifications have been identified Initial studies in cuvettes will identify successful formulations which will then be scaled up to relevant D dosimeter dimensions for evaluation by the DUKE optical scanner The second aim will beis the optimization of the DUKE optical CT scanner for commercial application in a general clinic which will be conducted by the co PI Dr Oldham of DUKE Prior scanners have worked defined state of the art performance well but require expensive telecentric optical lenses and large volumes of refractive index matching fluids and substantial expertise making the system impractical for the general clinic In this aim we leverage new D printing techniques to solve both of these challenges through creation of a novel light collimating solid tank The proposed research develops a scanning system willwhich eliminates the need for both telecentric the lenses and minimize the amount ofalmost all of refractive index matching liquid This will be achieved by manufacturing a solid tank which both surrounds the dosimeter and collimates light into parallel ray geometry The long term goal is to commercialize the the Presage Optical CT system and meet the need for an economic but hugely capable fully D dosimetry system for the general clinic capable of in house use with re useable PRESAGE formulations or for remote offsite long distance credentialing type verification stable PRESAGE The Presage Optical CT D dosimetry system will be a listed FDA medical device commercially sold by Heuris Inc Project Narrative Radiation therapy is a principle treatment modality for many cancers In the last yearsdecade the sophistication and complexity of treatment delivery has increased dramatically Corresponding advances in treatment verification has lagged behind however creating a dangerous imbalance because comprehensive end to end treatment verification is widely recognized as essential to safe and effective treatment implementation This proposal will develop a novel state of the art and highly cost effective D dosimetry system that can provide a uniquely powerful solution to the problem of comprehensive end to end dosimetry verification